Let me go to the bathroom real quick and then we should finish up on relationships and supportive partners.

The impact of the frozen is getting to you, huh?

Or you're not using it?

Yeah, I've been experimented with here and there, but I have not, I just like, I had a refeed this weekend.

So I'm a water buffalo and then Tuesday it goes.

Yeah, I'll be right back.

On that topic, Derek, I've come to the realization that, you know,

canaglyphlosin has far better health profiles than impagliflosen.

Oh, really?

Yeah.

For those that are just listening, there are these drugs called GLSGLT2 inhibitors.

And they inhibit with different selectivity, SGLT2 over SGLT1.

The Mpaglphosen, the drug I've been using for a long time, is particularly selective of SGLT2.

It was thought originally when they designed these, they really wanted them to be selective.

But it turns out a lot of these very interesting studies now show that cardiovascular protective effects from SGLT1 inhibitions.

So for example, SGLT1 appears to be upregulated in the left

ventricle of people with heart failure and blocking it directly seems very valuable. So there's a lot of

studies now showing cardiovascular protective effects from specifically canaglozine or depaglofen

but not impaglozin oraglofen but not in paglofen or more interestingly there are

new papers from the last two years proposing that sGLT2 inhibitors be considered and be repurposed

as anti-cancer drugs so if you were to propose like the most heavy hitting and like when we last time we did a bodybuilder ancillary's video, it was like an hour.

If you were to add if you were to summer, if you were to summarize like that hour long video into like just the compounds themselves, the SL, SGLT2 inhibitor that you just mentioned what what was it called again can that

...